Pharmacovigilance Office, Ministry of Health, Kuwait.
Faculty of Health & Applied Sciences, University of the West of England, Bristol, UK.
Res Social Adm Pharm. 2024 Feb;20(2):86-98. doi: 10.1016/j.sapharm.2023.10.004. Epub 2023 Oct 18.
BACKGROUND: Adverse drug reactions (ADRs) are known to cause hospitalisation, longer hospital stays, as well as higher healthcare costs and mortality. Unrecognised ADRs are anticipated throughout the medicine lifecycle as, before the medicine reaches the market, clinical trials are conducted for a short period on a limited number of people, who might underrepresent the actual population. After the medicine reaches the market, emergent information that could affect its benefit-to-risk balance is usually shared by regulatory agencies and pharmaceutical companies through medicine risk communications. Medicines risk communications aim to prevent harm to patients by targeting their behaviour, knowledge, and attitudes, as well as those of health care professionals (HCPs). Despite their important role in translating these communications into their clinical practice, HCPs do not always adhere to the recommendations provided in risk communications. Measurement of medicine risk communications' effectiveness does not necessarily guarantee their implementation, cost-effectiveness, or transferability in real-world situations. To enhance the impact of drug regulatory interventions, implementation science has been encouraged. However, implementation science was not previously used to identify factors affecting HCPs' implementation of medicines risk communications. A recently widely used framework is the Theoretical Domain Framework (TDF). In this systematic review, the TDF was employed to categorise a range of different factors that could affect HCPs' implementation of medicine risk communications within their clinical contexts. METHODS: The search strategy involved a set of predefined search terms and fifteen databases, such as EMBASE, PubMed, Web of Science and CINAHL PLUS. Searches were conducted from April to May 2018 and updated in June 2021 using PubMed, Scopus, and CINAHL PLUS. A second reviewer independently conducted the screening process of the initial search. The total number of records screened was 10,475. A study was included if it reported any factors influencing HCPs' uptake of medicine risk communications. Only studies with English or Arabic abstracts were included. Those studies that did not include pharmacovigilance-related medicine risk communications were excluded. Additionally, studies only assessing HCPs' practice or evaluating the effectiveness of risk minimisation measures were excluded. Likewise, studies related to occupational hazards, case reports, interventional studies, and studies not involving HCPs were excluded. In case the published information was insufficient to decide whether to include or exclude a study, the authors were contacted. Furthermore, the authors of seven eligible abstracts were contacted for full-text articles. The mixed method appraisal tool (MMAT) was used to evaluate the quality of the included studies. All included studies were assessed by one reviewer, and a total of 16 studies were assessed by two reviewers independently. Disagreements were resolved through discussion. Using thematic analysis and concept mapping, a narrative synthesis was performed, followed by a critical reflection on the synthesis process. This review presents the results of the concept mapping, which involved matching the identified factors to the TDF. RESULTS: A total of 28 studies were included. Eleven domains influenced HCPs' implementation of medicine risk communications. A large number of studies included factors related to the "Knowledge" domain (n = 23), followed by "Beliefs about Consequences" (n = 13), "Memory, Attention and Decision Processes" (n = 12) and "Environmental Context and Resources" domains (n = 12). Seven studies reported "social influences" and six studies included factors relating to "Goals", followed by four studies involving factors related to "Social/Professional Role and Identity". Underrepresented domains included "Emotion" (n = 2), "Beliefs about Capabilities" (n = 2), "Behavioural Regulation" (n = 1), and "Reinforcement" (n = 1). On the other hand, none of the identified factors were related to the "Skills", "Optimism", or "Intentions" domains. Except for "Beliefs about Consequences", most studies contributing to the other three most commonly reported domains ("Knowledge"; "Environmental Context and Resources"; and "Memory, Attention and Decision Processes") scored low (1 or 2 out of 5) on the MMAT quality assessment. Moreover, the same number of studies (n = 5) contributing to the "Beliefs about Consequences" domain had low (1 or 2 out of 5), and intermediate (3 out of 5) scores on the MMAT. CONCLUSION: Medicines risk communications are important tools for disseminating information that may influence the benefit-to-risk balance of medicines. Even though HCPs are required to implement the recommendations of these communications, they do not always adhere to them. Using the TDF enabled the categorization of the range of factors that affect whether or not HCPs implement the recommendations provided in a medicine risk communication. However, most of these factors relate to four domains only ("Knowledge"; "Beliefs about Consequences"; "Memory, Attention and Decision Processes"; and "Environmental Context and Resources"). Additionally, most of the studies contributing to three of these four domains were of low quality. Future research should focus on using implementation science to identify target behaviours for actionable medicine risk communications. Regulators should use such science to develop cost-effective strategies for improving the implementation of medicines risk communication by HCPs.
背景:已知药物不良反应(ADR)会导致住院、住院时间延长,以及更高的医疗保健成本和死亡率。在药物生命周期中,预计会出现未被识别的 ADR,因为在药物进入市场之前,临床试验仅在有限数量的人群中进行了短期的研究,这些人群可能无法代表实际人群。药物进入市场后,监管机构和制药公司通常会通过药物风险沟通来分享可能影响其获益-风险平衡的紧急信息。药物风险沟通旨在通过针对患者、医疗保健专业人员(HCP)的行为、知识和态度来预防伤害。尽管他们在将这些信息转化为临床实践方面发挥了重要作用,但 HCP 并不总是遵守风险沟通中提供的建议。衡量药物风险沟通的有效性并不能保证其在现实情况下的实施、成本效益或可转移性。为了增强药物监管干预的效果,已经鼓励实施科学。然而,实施科学以前并未用于确定影响 HCP 实施药物风险沟通的因素。一个最近广泛使用的框架是理论领域框架(TDF)。在这项系统评价中,TDF 被用于对可能影响 HCP 在其临床环境中实施药物风险沟通的一系列不同因素进行分类。
方法:搜索策略涉及一套预设的搜索词和十五个数据库,如 EMBASE、PubMed、Web of Science 和 CINAHL PLUS。搜索于 2018 年 4 月至 5 月进行,并于 2021 年 6 月使用 PubMed、Scopus 和 CINAHL PLUS 进行了更新。由第二位评审员独立进行初始搜索的筛选过程。筛选的记录总数为 10475 条。如果研究报告了任何影响 HCP 接受药物风险沟通的因素,则纳入研究。仅纳入有英文或阿拉伯文摘要的研究。排除不涉及药物警戒相关药物风险沟通的研究。此外,仅评估 HCP 实践或评估风险最小化措施有效性的研究也被排除在外。同样,与职业危害、病例报告、干预性研究以及不涉及 HCP 的研究相关的研究也被排除在外。如果发表的信息不足以决定是否纳入或排除某项研究,则联系作者。此外,还联系了七项合格摘要的作者以获取全文文章。使用混合方法评估工具(MMAT)评估纳入研究的质量。由一位评审员评估所有纳入的研究,由两位评审员独立评估 16 项研究。通过讨论解决分歧。使用主题分析和概念映射,进行了叙述性综合,然后对综合过程进行了批判性反思。本综述介绍了概念映射的结果,其中包括将确定的因素与 TDF 进行匹配。
结果:共纳入 28 项研究。11 个领域影响 HCP 实施药物风险沟通。大量研究包括与“知识”领域相关的因素(n=23),其次是与“后果信念”(n=13)、“记忆、注意力和决策过程”(n=12)和“环境背景和资源”领域相关的因素(n=12)。有 7 项研究报告了“社会影响”,6 项研究包括与“目标”相关的因素,其次是与“社会/专业角色和身份”相关的 4 项研究。代表性不足的领域包括“情绪”(n=2)、“能力信念”(n=2)、“行为调节”(n=1)和“强化”(n=1)。另一方面,没有一个确定的因素与“技能”、“乐观”或“意图”领域有关。除了“后果信念”之外,对其他三个最常报告的领域(“知识”;“环境背景和资源”;和“记忆、注意力和决策过程”)做出贡献的大多数研究(n=5)的 MMAT 质量评估得分较低(5 分中得 1 分或 2 分)。此外,对“后果信念”领域做出贡献的相同数量的研究(n=5)的 MMAT 得分也较低(1 分或 2 分)和中等(3 分)。
结论:药物风险沟通是传播可能影响药物获益-风险平衡信息的重要工具。尽管 HCP 被要求实施这些沟通的建议,但他们并不总是遵守这些建议。使用 TDF 能够对影响 HCP 是否实施药物风险沟通中建议的一系列因素进行分类。然而,这些因素大多与四个领域有关(“知识”;“后果信念”;“记忆、注意力和决策过程”;和“环境背景和资源”)。此外,对这四个领域中的三个做出贡献的大多数研究质量都较低。未来的研究应侧重于使用实施科学来确定针对药物风险沟通的可操作的目标行为。监管机构应利用这种科学为改善 HCP 实施药物风险沟通制定具有成本效益的策略。
JBI Database System Rev Implement Rep. 2016-4
Cochrane Database Syst Rev. 2018-1-16
Cochrane Database Syst Rev. 2022-5-20
JBI Database System Rev Implement Rep. 2016-4
Health Technol Assess. 2001
Diagnostics (Basel). 2025-6-19